Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

SIMPLE SUMMARY: Ibrutinib demonstrated superior efficacy compared to chemoimmunotherapy in patients with chronic lymphocytic leukemia. However, adverse events are a frequent reason for treatment discontinuation. This study was aimed to evaluate the incidence, risk factors, and prognostic impact of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauro, Francesca Romana, Giannarelli, Diana, Visentin, Andrea, Reda, Gianluigi, Sportoletti, Paolo, Frustaci, Anna Maria, Chiarenza, Annalisa, Ciolli, Stefania, Vitale, Candida, Laurenti, Luca, De Paoli, Lorenzo, Murru, Roberta, Gentile, Massimo, Rigolin, Gian Matteo, Levato, Luciano, Giordano, Annamaria, Del Poeta, Giovanni, Stelitano, Caterina, Ielo, Claudia, Noto, Alessandro, Guarente, Valerio, Molica, Stefano, Coscia, Marta, Tedeschi, Alessandra, Gaidano, Gianluca, Cuneo, Antonio, Foà, Robin, Martelli, Maurizio, Girmenia, Corrado, Gentile, Giuseppe, Trentin, Livio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269042/
https://www.ncbi.nlm.nih.gov/pubmed/34209515
http://dx.doi.org/10.3390/cancers13133240

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8269042/
https://www.ncbi.nlm.nih.gov/pubmed/34209515
http://dx.doi.org/10.3390/cancers13133240

Ejemplares similares